C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.
This is a preview. Log in through your library . Abstract The transcription factor Nrf2 is an important modulator of antioxidant and drug metabolism, carbohydrate and lipid metabolism, as well as heme ...
• Activation of nuclear factor erythroid 2-related factor 2 (Nrf2) significantly reduces the accumulation of senescent bronchial epithelial cells in chronic obstructive pulmonary disease (COPD) models ...
Cellular stress, or oxidative stress, occurs when there is a buildup of reactive oxygen species (ROS), which interferes with cellular mechanisms and can even cause damage to proteins, lipids, and DNA.